Latest news with #KurosBiosciences
Business Insider
16 hours ago
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Kuros Biosciences (OtherCSBTF), CSL (OtherCMXHF) and Roche Holding AG (OtherRHHVF)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kuros Biosciences (CSBTF – Research Report), CSL (CMXHF – Research Report) and Roche Holding AG (RHHVF – Research Report) with bullish sentiments. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Kuros Biosciences (CSBTF) Kepler Capital analyst Christophe dombu maintained a Buy rating on Kuros Biosciences on June 16 and set a price target of CHF32.50. The company's shares closed last Wednesday at $33.22, close to its 52-week high of $36.10. According to dombu is ranked #8486 out of 9621 analysts. The the analyst consensus on Kuros Biosciences is currently a Hold rating. CSL (CMXHF) Morgan Stanley analyst David Bailey maintained a Buy rating on CSL today and set a price target of A$303.00. The company's shares closed last Tuesday at $148.56. According to Bailey is a 4-star analyst with an average return of 16.4% and a 48.1% success rate. Bailey covers the Healthcare sector, focusing on stocks such as Fisher & Paykel Healthcare Corporation Limited, Ramsay Health Care, and Cochlear. CSL has an analyst consensus of Strong Buy, with a price target consensus of $203.87, implying a 37.2% upside from current levels. In a report released yesterday, Jarden also maintained a Buy rating on the stock with a A$317.61 price target. Roche Holding AG (RHHVF) Kepler Capital analyst David Evans maintained a Buy rating on Roche Holding AG on June 16 and set a price target of CHF315.00. The company's shares closed last Tuesday at $321.13. According to Evans is ranked #4919 out of 9621 analysts. The word on The Street in general, suggests a Hold analyst consensus rating for Roche Holding AG with a $352.85 average price target, implying an 8.3% upside from current levels. In a report issued on June 16, UBS also maintained a Buy rating on the stock with a CHF314.00 price target.
Yahoo
5 days ago
- Business
- Yahoo
Kuros Biosciences AG (VTX:KURN) surges 4.9%; individual investors who own 59% shares profited along with insiders
Significant control over Kuros Biosciences by individual investors implies that the general public has more power to influence management and governance-related decisions 41% of the business is held by the top 25 shareholders 24% of Kuros Biosciences is held by insiders Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. If you want to know who really controls Kuros Biosciences AG (VTX:KURN), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 59% to be precise, is individual investors. In other words, the group stands to gain the most (or lose the most) from their investment into the company. Individual investors gained the most after market cap touched CHF995m last week, while insiders who own 24% also benefitted. In the chart below, we zoom in on the different ownership groups of Kuros Biosciences. Check out our latest analysis for Kuros Biosciences Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. As you can see, institutional investors have a fair amount of stake in Kuros Biosciences. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Kuros Biosciences, (below). Of course, keep in mind that there are other factors to consider, too. Hedge funds don't have many shares in Kuros Biosciences. The company's largest shareholder is C. Oomen, with ownership of 22%. Meanwhile, the second and third largest shareholders, hold 3.8% and 3.3%, of the shares outstanding, respectively. A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar. The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Our information suggests that insiders maintain a significant holding in Kuros Biosciences AG. Insiders own CHF234m worth of shares in the CHF995m company. That's quite meaningful. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling. The general public -- including retail investors -- own 59% of Kuros Biosciences. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions. We can see that Private Companies own 3.8%, of the shares on issue. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company. It's always worth thinking about the different groups who own shares in a company. But to understand Kuros Biosciences better, we need to consider many other factors. Case in point: We've spotted 1 warning sign for Kuros Biosciences you should be aware of. If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
13-05-2025
- Business
- Yahoo
Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Market Day in Zürich
Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Markets Day in Zürich Schlieren (Zürich), Switzerland, May 13, 2025 – Kuros Biosciences ('Kuros' or the 'Company') a leader in innovative biologic technologies, is pleased to announce today's Capital Markets Day on Tuesday, May 13, 2025, at 9am CEST, at the Hyatt Regency Zürich Airport, The Circle, Zürich, Switzerland. The event will also be available virtually via live webcast. Capital Markets Day will provide institutional investors, analysts, and the media with an opportunity to hear directly from the Kuros leadership team about the company's breakthrough science, global commercial strategy, and transformative approach to bone healing. Attendees will gain valuable insights into the market performance of MagnetOs, its clinical efficacy, and the company's strategic priorities. Kuros will also provide updates on its expanding global footprint, new market opportunities, and continued innovation in both spinal and extremity applications. Joining the Kuros leadership team will be a U.S. orthopedic surgeon explaining the power of MagnetOs from the surgeon and patient perspective. Key highlights of the presentation will include: An overview of MagnetOs, Kuros' proprietary bone healing technology, which has been shown to deliver more predictable fusions in surgical procedures. In a Level I human clinical study published in Spine, MagnetOs demonstrated nearly twice the fusion rate of autograft, with even more significant results among active smokers which is traditionally a high-risk patient group.*1-3 MagnetOs grows bone on its own thanks to NeedleGrip™ – a proprietary submicron surface technology that harnesses the immune system to stimulate bone growth without added cells or growth factors.†4-9 Kuros's global commercial strategy, including the ongoing expansion of MagnetOs across new markets. The company is targeting both spinal and extremity markets, with an anticipated growth trajectory in the U.S., Europe, and many markets in the rest of the world. Kuros is also leveraging its strategic alliance with Medtronic to broaden market access and accelerate product adoption globally. A look at Kuros' commitment to science, with seven Level I human clinical trials currently underway, demonstrating the ability of MagnetOs to promote bone growth and fusion across various surgical applications. Surgeon perspective with a patient story and clinical insights from Dr. Greg Berlet, a leading orthopedic surgeon, sharing firsthand experiences and explaining why MagnetOs is becoming the preferred choice for surgeons in extremity surgeries. How Kuros is transforming the business to manage the company's strong growth and achieve operational leverage. "Kuros is at the forefront of science and innovation in the orthobiologic space, and we are thrilled to share the progress we have made with MagnetOs as well as our long-term vision," said Chris Fair, CEO of Kuros Biosciences. "As we scale our business and expand into new markets, we are committed to improving patient outcomes and driving shareholder value through continued innovation, strategic partnerships, and global growth." Webcast Virtual access: Join the live webcast For further information, please contact: Alexandre Müller Daniel Geiger Investor Relations Chief Financial Officer Tel +41 43 268 32 31 Tel +41 44 733 47 41 IR@ MagnetOsTM is a bone graft like no other: thanks to its NeedleGripTM surface technology, it grows bone even in soft tissues.‡10 This surface technology provides traction for our body's vitally important 'pro-healing' immune cells (M2 macrophages).†§4,10 This in turn, unlocks previously untapped potential to stimulate stem cells – and form new bone throughout the graft.†¶11-13 The growing body of science behind NeedleGrip is called osteoimmunology. But for surgeons and their patients it means one thing: a more predictable fusion.†#4 Please refer to the instructions for use for your local region for a full list of indications, contraindications, warnings, and precautions. Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company's first commercial product, MagnetOsTM, is a unique advanced bone graft that has already been used across four continents. For more information on the company, its products and pipeline, visit This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words 'will' or 'expect' or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments. * Radiographic fusion data of the smoker subgroup were not statistically analyzed as a subgroup and were not included in the peer-reviewed publication of the study.1† Results from in vitro or in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit In large animal models.§ MagnetOs is not cleared by the FDA as an osteoinductive bone graft.¶ For a 510(k)-cleared synthetic bone graft.# MagnetOs has been proven to generate more predictable fusions than two commercially available alternatives in an ovine model of posterolateral fusion. 1. Stempels, et al. Spine. 2024;49(19):1323-1331. 2. Van Dijk, LA. 24th SGS Annual Meeting (Swiss Society of Spinal Surgery). Basel, Switzerland. Aug 2024. 3. Berman, et al. Int J Spine Surg. 2017;11(4):29. 4. Van Dijk, et al. eCM. 2021;41:756-73. 5. Van Dijk, et al. J Immunol Regen Med. 2023;19:100070. 6. Instructions for Use (IFU) MagnetOs Granules (US). 7. Instructions for Use (IFU) MagnetOs Putty (US). 8. Instructions for Use (IFU) MagnetOs Easypack Putty (US). 9. Instructions for Use (IFU) MagnetOs Flex Matrix (US). 10. Duan, et al. eCM. 2019;37:60-73. 11. Van Dijk, et al. JOR Spine. 2018;e1039. 12. Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater. 2019;107(6):2080-2090. 13. Van Dijk, et al. Clin Spine Surg. 2019;33(6):E276-E287. Attachment Kuros Press Release Capital Market Day 5-13-25Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
11-03-2025
- Business
- Associated Press
Kuros Biosciences grows sales to CHF 75.6 million for 2024
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences grows sales to CHF 75.6 million for 2024 Financial Highlights Direct MagnetOs™ sales increased by 136% to CHF 74.8 million (2023: CHF 31.7 million) Total Medical Device sales rose by 125% to CHF 75.6 million (2023: CHF 33.6 million) Total Group EBITDA reached CHF 2.2 million (2023: EBITDA loss of CHF (5.9) million), including the impairment, the group ended in a net loss of CHF (4.3) million Total Group adjusted EBITDA amounted to CHF 9.0 million, equaling a margin of 11.9% The Group surpassed the cash flow breakeven point on an annualized basis Cash and cash equivalents totaled CHF 18.0 million, up from CHF 14.2 million as of December 31, 2023 In 2025 Kuros will change its reporting currency from CHF to USD The Group expects sales growth of at least 60% in 2025 and anticipates sales of between USD 220 million and USD 250 million by 2027 Kimberley Elting proposed as new Board member Schlieren (Zurich), Switzerland, March 11, 2025 – Kuros Biosciences ('Kuros' or the 'Company') a leader in next generation bone healing technologies, today announced its financial and operational results for the full year 2024, marking another year of record growth, increased market penetration, and strategic portfolio advancements. Revenue from Direct MagnetOs product sales increased 136% year-on-year to CHF 74.8 million (2023: CHF 31.7 million). Total group revenue reached CHF 75.6 million, marking a growth of 125% compared to 2023. Kuros Group achieved an EBITDA of CHF 2.2 million in 2024, increased from EBITDA loss of CHF (5.9) million in 2023; adjusted EBITDA excluding the Fibrin-PTH costs, recurring and one-time share-based compensation, and the relevant social security charges totaled at CHF 9.0 million, representing an adjusted EBITDA margin of 11.9%. Chris Fair, Chief Executive Officer of Kuros Biosciences, said: 'We recorded exceptional Direct MagnetOs sales growth of 136%. This growth was driven by the successful roll-out of our technology in key markets, particularly as demand continues to grow globally. Overall, this was a transformative year for Kuros, marked by delivering our first positive EBITDA for the Group much earlier than anticipated. In addition, exceeding cash flow breakeven is a key milestone for the company. Strategically, a landmark Level 1 clinical study published in Spine continues to drive customer preference. We also secured a five-year exclusive agreement with Medtronic to accelerate MagnetOs adoption in the U.S. Our expansion into adjacent extremities markets, portfolio innovation in minimally invasive surgery, and broader global distribution capabilities position us for continued explosive growth. With a strong foundation and a clear roadmap, Kuros is well-positioned to capitalize on emerging opportunities and drive sustained shareholder value.' Regulatory, Clinical & Commercial Highlights Landmark Clinical Data Published – A peer-reviewed Level 1 clinical study in Spine confirmed MagnetOs as a standalone alternative to autograft, showing noninferiority, with primary analysis even indicating MagnetOs superiority. MagnetOs achieved a 79% fusion rate, outperforming autograft's 47% in challenging spinal posterolateral fusions.1,2 U.S. Consolidation and Growth – A five-year strategic agreement with the Medtronic spinal division enhanced MagnetOs' access and will accelerate its growth and adoption across the U.S. Under the agreement, Medtronic acts as the exclusive sales agent of MagnetOs for Kuros Biosciences USA, Inc. in mutually agreed upon sales territories for use in spine surgeries. Diversification into Adjacent Markets – Kuros initiated the expansion into the adjacent extremities markets, leveraging the established success of MagnetOs in the spine market and pursuing new indications in other musculoskeletal areas. Portfolio Innovation – Significant development work was completed for new MagnetOs Minimally Invasive Surgery (MIS) applications and osteopromotive platforms, including surface technologies for implantable devices, to meet market needs. Global Expansion – Kuros expanded its distribution network in the UK, Australia, New Zealand and the Middle East, with plans to enter Asia Pacific and South American markets in 2025. Operational Excellence – Kuros doubled its capacity in August 2024 and is set to double capacity again to meet anticipated growth, focusing on maximizing return on capital through strategic resource allocation and controlled fixed costs for improved operational leverage. New Board Member – Kimberley Elting, an experienced MedTech executive with comprehensive global industry expertise and significant leadership experience across all medical technology company operations and product life cycle, is proposed as a new Board member. Kimberley's background in the U.S. and global commercialization, the orthopedics market, and company governance matters would complement the existing Kuros Board of Directors. She has held executive leadership positions at Orthofix Medical, Inc., Trivascular Technologies (now Endologix) and St. Jude Medical (now Abbott). Net operating costs Cost of goods sold amounted to CHF 13.5 million (2023: CHF 9.6 million) of which CHF 1.6 million (2023: CHF 1.8 million) relate to the amortization of capitalized R&D and CHF 5.1 million related to impairment of goodwill. (2023: impairment of goodwill and intangible of CHF 4.4 million and CHF 0.1 million respectively). Net operating costs from continuing operations amounted to CHF 67.0 million, compared to CHF 33.6 million in the prior year. Sales and marketing costs increased from CHF 23.3 million in 2023 to CHF 45.0 million in 2024, primarily driven by an expanded sales force, higher sales and distribution expenses, reflecting the growth in commercial activities. Research and development costs increased from CHF 2.0 million in 2023 to CHF 7.0 million in 2024. This is primarily driven by increased R&D activities, clinical trial expenditures, and higher personnel expenses due to an increase in headcount and share-based compensation. General and administrative costs increased from CHF 8.4 million in 2023 to CHF 15.2 million in 2024. The increase was mainly driven by the scaling up of back-office functions to support business growth. In prior years, the Group explored drug-based orthobiologic development, namely Fibrin-PTH. Following an interim analysis and the superior clinical outcomes observed with MagnetOs, the Group decided in December 2023 not to advance Fibrin-PTH to Phase 3. All operations related to Fibrin-PTH have ceased by the end of 2024, resulting in the classification of Fibrin-PTH as discontinued operation. In 2024, expenses related to discontinued operation totaled CHF 0.6 million (2023: CHF 3.6 million). Financial position and other assets Cash and cash equivalents amounted to CHF 18.0 million. The increase is mainly driven by higher operating cash flow from increased revenue and proceeds from option exercises. Funds available (including trade and other receivables) for financing the operations of Kuros amounted to CHF 34.2 million as of December 31, 2024. This is an increase of CHF 12.4 million from CHF 21.8 million as of December 31, 2023. As of December 31, 2024, total intangible assets amounted to CHF 15.0 million (2023: CHF 16.5 million) and goodwill amounted to CHF 19.4 million (2023: CHF 24.5 million). The impairment of goodwill of CHF 5.1 million resulted from a delay of expected milestones from Checkmate licensing. Outlook Kuros expects MagnetOs to continue its strong growth trajectory in the spine and extremity segments, gaining further market share in the U.S., Europe and the rest of the world, and launching in additional countries. The company is sufficiently financed on its planned organic growth path and expects robust sales growth of at least 60% in 2025. Kuros is anticipating sales of USD 220 to 250 million by 2027, reflecting its commitment to long-term value creation through innovation, market share gains, and customer satisfaction. Key figures 2024 2023 Restated In TCHF, IFRS Revenue from product sales 75,555 33,564 Cost of goods sold (13,524) (9,628) Gross profit 62,031 23,936 Sales and marketing costs (44,964) (23,328) Research and development costs (6,984) (2,030) General and administrative costs (15,196) (8,447) Other income 118 248 Net operating costs (67,026) (33,557) Operating loss (4,995) (9,621) Net finance result 1,649 (155) Loss before tax (3,346) (9,776) Income taxes (370) (380) Net loss from continuing operations (3,716) (10,156) Loss from discontinued operation, net of tax (574) (3,571) Net loss (4,290) (13,727) Net loss per share from continuing operations (in CHF) (0.10) (0.28) Net loss per share (in CHF) (0.12) (0.38) Cash and cash equivalents 18,021 14,208 Trade and other receivables 16,139 7,617 Annual Report 2024 The Kuros Biosciences Annual Report 2024 can be downloaded via the following link on our website: Kuros Biosciences Annual Report 2024 Full Year Results 2024 – Webcast Kuros will host a virtual webcast to discuss FY 2024 financial results on March 11, 2025, at 3:00pm CET. Investors can join the webcast via the following link: Investor Webcast Registration Upcoming Events April 15, 2025 – Annual Shareholders' Meeting 2025 April 17, 2025 – Trading Update Q1 2025 May 13, 2025 – Kuros Capital Market Day For further information, please contact: Kuros Biosciences AG About MagnetOs MagnetOs TM is a bone graft like no other: thanks to its NeedleGrip TM surface technology, it grows bone even in soft tissues. This surface technology provides traction for our body's vitally important 'pro-healing' immune cells (M2 macrophages). This in turn, unlocks previously untapped potential to stimulate stem cells – and form new bone throughout the graft. The growing body of science behind NeedleGrip is called osteoimmunology. But for surgeons and their patients it means one thing: a more predictable fusion. *†‡3-7 Indications Statement Please refer to the instructions for use for your local region for a full list of indications, contraindications, warnings, and precautions. About Kuros Biosciences Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company's first commercial product, MagnetOs TM, is a unique advanced bone graft that has already been used across four continents. For more information on the company, its products and pipeline, visit Forward Looking Statements This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words 'will' or 'expect' or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments. *Results from in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit †MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft. ‡MagnetOs has been proven to generate more predictable fusions than two commercially available alternatives in an ovine model of posterolateral fusion. Stempels, H. et al., 'Efficacy of biphasic calcium phosphate ceramic with a needle-shaped surface topography versus autograft in instrumented posterolateral spinal fusion: A randomized trial.' Spine. June 17, 2024. Yadav S, et al. J Ortho Trauma Rehab. 2020;27(2):173-178. Van Dijk, et al. eCM. 2021; 41:756-73. Duan, et al. eCM. 2019; 37:60-73. Van Dijk, et al. Clin Spine Surg. 2020;33(6): E276-E287. Van Dijk, et al. JOR Spine. 2018 ; e1039.
